Marc Y. Donath

Active 1994–2025

94
Papers
28,443
Citations
72
h-index
93
i10-index

Citations

Citations per year for Marc Y. Donath1976: 1 citations1994: 2 citations1996: 3 citations1997: 4 citations1998: 4 citations1999: 14 citations2000: 9 citations2001: 20 citations2002: 38 citations2003: 55 citations2004: 98 citations2005: 97 citations2006: 96 citations2007: 130 citations2008: 189 citations2009: 239 citations2010: 307 citations2011: 350 citations2012: 402 citations2013: 463 citations2014: 370 citations2015: 363 citations2016: 293 citations2017: 355 citations2018: 382 citations2019: 1,147 citations2020: 1,239 citations2021: 1,146 citations2022: 912 citations2023: 780 citations2024: 1,224 citations2025: 710 citations2026: 24 citations1977–1993: no citations, so these years are not shown1995: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,676 citing papers, 21.4% of this breakdownChina: 1,755 citing papers, 14% of this breakdownUnited Kingdom: 746 citing papers, 5.9% of this breakdownGermany: 639 citing papers, 5.1% of this breakdownItaly: 578 citing papers, 4.6% of this breakdownCanada: 461 citing papers, 3.7% of this breakdownSwitzerland: 381 citing papers, 3% of this breakdownAustralia: 363 citing papers, 2.9% of this breakdownFrance: 347 citing papers, 2.8% of this breakdownNetherlands: 334 citing papers, 2.7% of this breakdownSpain: 299 citing papers, 2.4% of this breakdownJapan: 288 citing papers, 2.3% of this breakdown
0%21.4%Other 29.2%

Fields

  • Medicine56.5%
  • Biochemistry, Genetics and Molecular Biology24.8%
  • Immunology and Microbiology8.9%
  • Neuroscience3.1%
  • Nursing1.8%
  • Agricultural and Biological Sciences1.3%
  • Other3.6%

Topics

  • Adipokines, Inflammation, and Metabolic Diseases6.1%
  • Pancreatic function and diabetes5.7%
  • Diabetes and associated disorders3.9%
  • Inflammasome and immune disorders3.4%
  • Adipose Tissue and Metabolism3.2%
  • Diabetes Treatment and Management2%
  • Other75.7%

Coauthors

All papers

Open in search
  1. Inflammation in obesity, diabetes, and related disorders

    Authors: , , , - Immunity 2022 cited by 1,932

  2. Type 2 diabetes as an inflammatory disease

    Authors: , - Nature reviews. Immunology 2011 cited by 3,688

  3. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hiroaki Shimokawa, Irina Veze, Birutė Petrauskienė, Leon Salvador, John J.P. Kastelein, Jan H. Cornel, Tor Ole Klemsdal, Félix Medina, Andrzej Budaj, L Vida-Simiti, Zhanna Kobalava, Petar Otašević, Daniel Pella, Mitja Lainščak, Ki‐Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Y. Donath, Juey‐Jen Hwang, Hakan Kültürsay, Marcus Flather, Christie M. Ballantyne, Seth Bilazarian, William H. Chang, Cara East, Brendan Everett, Les B. Forgosh, Robert J. Glynn, Barry Harris, Peter Libby, M Ligueros, Tom Thurén, Erin A. Bohula, Bindu Charmarthi, Susan Cheng, Sherry Chou, Jacqueline Suk Danik, Graham T. McMahon, Bradley A. Maron, MingMing Ning, Benjamin A. Olenchock, Reena L. Pande, Todd S. Perlstein, Aruna D. Pradhan, Natalia S. Rost, Aneesh B. Singhal, Viviany R. Taqueti, Nancy Wei, Howard A. Burris, Angela Cioffi, Anne Marie Dalseg, Nilanjan Ghosh, Julie R. Gralow, Tina Mayer, Hope S. Rugo, Vance G. Fowler, Ajit P. Limaye, Sara E. Cosgrove, Donald P. Levine, Renato D. Lópes, John Scott, Tom Thurén, M Ligueros, Robert Hilkert, Georgia Tamesby, Carolyn Mickel, Brian Manning, Julian Woelcke, Monique Tan, S Manfreda and 19 more - The Lancet 2017 cited by 1,308

  4. A guiding map for inflammation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frank L. van de Veerdonk, Charles A. Dinarello - Nature Immunology 2017 cited by 823

  5. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tamás Forster, Axel F. Sigurðsson, Prem Pais, Alessandro Fucili, Hisao Ogawa, Hiroaki Shimokawa, Irina Veze, Birutė Petrauskienė, Leon Salvador, Jan H. Cornel, Tor Ole Klemsdal, Félix Medina, Andrzej Budaj, L Vida-Simiti, Zhanna Kobalava, Petar Otašević, Daniel Pella, Mitja Lainščak, Ki‐Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Y. Donath, Juey‐Jen Hwang, Hakan Kültürsay, Marcus Flather, Christie M. Ballantyne, Seth Bilazarian, William H. Chang, Cara East, Les B. Forgosh, Barry Harris, M Ligueros - The Lancet 2017 cited by 886

  6. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2011 cited by 918

  7. Targeting innate immune mediators in type 1 and type 2 diabetes

    Authors: , , - Nature reviews. Immunology 2019 cited by 418

  8. Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus

    Authors: , , , , , , , - New England Journal of Medicine 2007 cited by 1,793

  9. Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Immunology 2017 cited by 389

  10. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes

    Authors: , , , , , , , , - Journal of the American College of Cardiology 2018 cited by 327

  11. Increased Number of Islet-Associated Macrophages in Type 2 Diabetes

    Authors: , , , , , , , , , , , , , - Diabetes 2007 cited by 779

  12. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas Mandrup‐Poulsen - The Lancet 2013 cited by 354

  13. Targeting inflammation in the treatment of type 2 diabetes: time to start

    Authors: - Nature Reviews Drug Discovery 2014 cited by 682

  14. Free Fatty Acids Induce a Proinflammatory Response in Islets via the Abundantly Expressed Interleukin-1 Receptor I

    Authors: , , , , , , , , , , - Endocrinology 2009 cited by 340

  15. The Role of Inflammation in β-cell Dedifferentiation

    Authors: , , , , , , , - Scientific Reports 2017 cited by 199

  16. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets

    Authors: , , , , , , , , - Journal of Clinical Investigation 2002 cited by 1,119

  17. Physiological role of cytokines in the regulation of mammalian metabolism

    Authors: , , , - Trends in Immunology 2023 cited by 57

  18. Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications

    Authors: , , , - Diabetes Care 2016 cited by 261

  19. The cephalic phase of insulin release is modulated by IL-1β

    Authors: , , , , , , , , , , , , , - Cell Metabolism 2022 cited by 62

  20. Interleukin-6 regulates pancreatic α-cell mass expansion

    Authors: , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 271

  21. Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease

    Authors: , , - Endocrine Reviews 2019 cited by 127

  22. Targeting the NLRP3 inflammasome–IL-1β pathway in type 2 diabetes and obesity

    Authors: , , - Diabetologia 2024 cited by 72

  23. Monounsaturated Fatty Acids Prevent the Deleterious Effects of Palmitate and High Glucose on Human Pancreatic β-Cell Turnover and Function

    Authors: , , , , - Diabetes 2003 cited by 548

  24. Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

    Authors: , , , , , , , , , - Diabetes Care 2012 cited by 308